Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

The Healthcare Businesswomen's Association (HBA) successfully convened the second edition of its annual India Leadership Summit (ILS) at The Lalit Hotel, Mumbai. Under the powerful theme "Winning a ...

Using Your Credit Card at the Checkout Is Set to Get a Lot More Complicated At Kris Jenner's birthday bash in Beverly Hills, ...

"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the body's own defences to attack cancer," said Ken Takeshita, the Japanese ...

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with ...

Companies don’t generally cut prices out of generosity.

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...